ProfileGDS5678 / 1416886_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 71% 60% 59% 55% 58% 54% 56% 56% 56% 57% 62% 56% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.56359
GSM967853U87-EV human glioblastoma xenograft - Control 24.4601471
GSM967854U87-EV human glioblastoma xenograft - Control 33.6110260
GSM967855U87-EV human glioblastoma xenograft - Control 43.4868359
GSM967856U87-EV human glioblastoma xenograft - Control 53.3459555
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5879458
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4270154
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4264956
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3766856
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3884156
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4389957
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6674562
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4400156
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3705755